Our study sheds highlight on the promising role of CREB3L1 as a prognostic biomarker, and an effective predictor for the immunotherapeutic efficacy and drug sensitivity in pan-cancer, as well as the potential mechanism by which CREB3L1 modulates the tumor immune microenvironment. This evidence concerns the gene CREB3L1 and cancer.